Manfred Koegl

Dr. Manfred Koegl


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2024 in Science
Verified
Journal Article
Closed access
JPJohannes Popow
Johannes Popow
WFWilliam Farnaby
William Farnaby
AGAndreas Gollner
Andreas Gollner
CKChristiane Kofink
Christiane Kofink
GFGerhard Fischer
Gerhard Fischer
ACAlessio Ciulli
Alessio Ciulli
Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein are highly prevalent in cancer. However, small-molecule concepts that address oncogenic KRAS alleles remain elusive beyond replacing glycine at position 12 with cysteine (G12C), which is clinically drugged through covalent inhibitors. Guided by biophysical and structural studies of ternary complexes, we designed a heterobifunctional small molecule that potently degrades 13 out of 17 of the most prevalent oncogenic KRAS alleles. Compared with inhibition, KRAS degradation results in more profound and sustained pathway modulation across a broad range of KRAS mutant cell lines, killing cancer cells while sparing models without genetic KRAS aberrations. Pharmacological degradation of oncogenic KRAS was tolerated and led to tumor regression in vivo. Together, these findings unveil a new path toward addressing KRAS-driven cancers with small-molecule degraders.

1 September 2017 in Cell Reports
Verified
Journal Article
Open access
NKNina Kerres
Nina Kerres
SSSteffen Steurer
Steffen Steurer
SSStefanie Schlager
Stefanie Schlager
GBGerd Bader
Gerd Bader
HBHelmut Berger
Helmut Berger
MKManfred Koegl
Manfred Koegl
The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL). Disruption of its interaction with transcriptional repressors interferes with the oncogenic effects of BCL6. We used a structure-based drug design to develop highly potent compounds that block this interaction. A subset of these inhibitors also causes rapid ubiquitylation and degradation of BCL6 in cells. These compounds display significantly stronger induction of expression of BCL6-repressed genes and anti-proliferative effects than compounds that merely inhibit co-repressor interactions. This work establishes the BTB domain as a highly druggable structure, paving the way for the use of other members of this protein family as drug targets. The magnitude of effects elicited by this class of BCL6-degrading compounds exceeds that of our equipotent non-degrading inhibitors, suggesting opportunities for the development of BCL6-based lymphoma therapeutics.

29 April 2015 in Plant Physiology
Verified
Journal Article
Open access
PDF file
MPMartina Pesch
Martina Pesch
ISIlka Schultheiß
Ilka Schultheiß
KKKarsten Klopffleisch
Karsten Klopffleisch
JUJoachim F. Uhrig
Joachim F. Uhrig
MKManfred Koegl
Manfred Koegl
MHMartin Hülskamp
Martin Hülskamp
The MBW (R2R3MYB, bHLH and WD40) genes comprise an evolutionarily conserved gene cassette that regulate several traits such as (pro)-anthocyanin and anthocyanin biosynthesis and epidermal cell differentiation in plants. Trichome differentiation in Arabidopsis thaliana is governed by GL1 (R2R3MYB), GL3 (bHLH) and TTG1 (WD40). They are thought to form a trimeric complex that acts as a transcriptional activation complex. We provide evidence that these three MBW proteins form either GL1 GL3 or GL3 TTG1 dimers. The formation of each dimer is counteracted by the respective third protein in yeast three hybrid assays, pull down experiments (LUMIER) and FLIM FRET studies. We further show that two target promoters, TRY and CPC, are differentially regulated: GL1 represses the activation of the TRY promoter by GL3 and TTG1 and TTG1 suppresses the activation of the CPC promoter by GL1 and GL3. Our data suggest that the transcriptional activation by the MBW complex involves alternative complex formation and that the two dimers can differentially regulate downstream genes.

1 April 2021 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
WFWilliam Farnaby
William Farnaby
MKManfred Koegl
Manfred Koegl
DMDarryl B. McConnell
Darryl B. McConnell
ACAlessio Ciulli
Alessio Ciulli

3 July 2024 in ACS Chemical Biology
Verified
Journal Article
Closed access
VVVesna Vetma
Vesna Vetma
LPLaura Casares Perez
Laura Casares Perez
JEJán Eliaš
Ján Eliaš
ASAndrea Stingu
Andrea Stingu
AKAnju Kombara
Anju Kombara
MKManfred Koegl
Manfred Koegl

3 March 2020 in Oncotarget
Verified
Journal Article
Open access
PDF file
SSStefanie Schlager
Stefanie Schlager
CSCarina Salomon
Carina Salomon
SOSabine Olt
Sabine Olt
CAChristoph Albrecht
Christoph Albrecht
AEAnja Ebert
Anja Ebert
MKManfred Koegl
Manfred Koegl
Https://doi.org/10.18632/oncotarget.27506 Stefanie Schlager, Carina Salomon, Sabine Olt, Christoph Albrecht, Anja Ebert, Oliver Bergner, Johannes Wachter, Francesca Trapani, Daniel Gerlach, Tilman...